Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 6,268 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Vitamin D and Calcium on Genes in the Colon

NCT00298545
View directory record Official record
Conditions
Colorectal Polyps, Colorectal Adenoma, Adenocarcinoma
Interventions
placebo and Calcitriol, Calcium and Calcitriol
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
48 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2011 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 3 Interventional Results available

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

NCT00444600
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
50
States / cities
Artesia, California • Beverly Hills, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
View directory record Official record
Conditions
Breast Cancer
Interventions
Sapanisertib, Fulvestrant, Exemestane
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 4 Interventional Results available

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

NCT02589600
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Interventions
Zoledronic acid, vitamin D, calcium, Saline
Drug · Dietary Supplement · Other
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New Kensington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Nov 3, 2026, 5:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study on the Bioequivalence of Vitamin D in Healthy Adults

NCT03552666
View directory record Official record
Conditions
Bioequivalence of Vitamin D in Healthy Adults
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Nov 3, 2026, 5:22 AM EST
Terminated Phase 2 Interventional

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

NCT00034528
View directory record Official record
Conditions
Hemoglobinopathies, Anemia, Sickle Cell, Hemoglobin SC Disease, Thalassemia, Thalassemia Major
Interventions
Busulfan, Fludarabine, FK506, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Nov 3, 2026, 5:22 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Comparison of Alcohol and Steroid Injection for Treating Morton's Neuroma

NCT00284583
View directory record Official record
Conditions
Morton's Neuroma
Interventions
Injection of Steroid into Foot, Injection of Alcohol into Foot, Injection of Lidocaine into Foot
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 1, 2006 · Synced Nov 3, 2026, 5:22 AM EST
Active, not recruiting Phase 1 Interventional

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Dexamethasone, Palbociclib, Sorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 1 Interventional Results available

A Study of LY3039478 in Participants With Advanced Cancer

NCT01695005
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Lymphoma
Interventions
LY3039478, Prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 3, 2026, 5:22 AM EST
Terminated Phase 2Phase 3 Interventional Results available

Cardiac Safe Transplants for Systemic Sclerosis

NCT03593902
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 4 Interventional Results available

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

NCT03817853
View directory record Official record
Conditions
Advanced Follicular Lymphoma
Interventions
Obinutuzumab, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Boulder, Colorado • Bethesda, Maryland • Florham Park, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177
View directory record Official record
Conditions
Pregnancy
Interventions
8% progesterone vaginal gel, Placebo Vaginal Gel
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
45
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Nov 3, 2026, 5:22 AM EST
Recruiting No phase listed Observational

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

NCT04331639
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 3, 2026, 5:22 AM EST
Completed Not applicable Interventional Results available

Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy

NCT01415583
View directory record Official record
Conditions
Post-operative Hemorrhage
Interventions
Dexamethasone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
3 Years to 18 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Nov 3, 2026, 5:22 AM EST
Terminated Phase 1 Interventional

A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

NCT04115956
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Melphalan-Flufenamide (Melflufen), Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 3, 2026, 5:22 AM EST
Withdrawn Phase 3 Interventional

Vitamin D Status in Patients With Severe Sepsis

NCT02684487
View directory record Official record
Conditions
Sepsis, Severe Sepsis, End Organ Damage, Multi Organ Failure
Interventions
vitamin D3, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 4 Interventional Results available

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

NCT01400516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Teriparatide, calcium citrate, Vitamin D, TNF antagonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Nov 3, 2026, 5:22 AM EST
Recruiting Phase 2 Interventional

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 2 Interventional Results available

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

NCT03439293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Daratumumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Anaheim, California • Denver, Colorado • Tallahassee, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Nov 3, 2026, 5:22 AM EST
Terminated Phase 4 Interventional Results available

Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo

NCT01760304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Budesonide / Formoterol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

NCT00732758
View directory record Official record
Conditions
Healthy
Interventions
Vitamin D3 1000 IU, Placebo Tablet
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 14 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Nov 3, 2026, 5:22 AM EST
Withdrawn Phase 4 Interventional

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115
View directory record Official record
Conditions
Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions
interferon beta 1a, methotrexate, methylprednisolone
Drug
Lead sponsor
MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Nov 3, 2026, 5:22 AM EST
Completed Phase 2 Interventional

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

NCT00002849
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, dexamethasone
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
40
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 3, 2026, 5:22 AM EST